Добро пожаловать в клуб

Показать / Спрятать  Домой  Новости Статьи Файлы Форум Web ссылки F.A.Q. Логобург    Показать / Спрятать

       
Поиск   
Главное меню
ДомойНовостиСтатьиПостановка звуковФайлыДефектологияКнижный мирФорумСловарьРассылкаКаталог ссылокРейтинг пользователейЧаВо(FAQ)КонкурсWeb магазинШкольникамКарта сайта

Поздравляем!
Поздравляем нового Логобуржца Королёва со вступлением в клуб!

Реклама

КНИЖНЫЙ МИР

Methylglyoxal-lowering agents as a treatment for Alzheimer''s disease?   Martina Krautwald

Methylglyoxal-lowering agents as a treatment for Alzheimer''s disease?

84 страниц. 2011 год.
LAP Lambert Academic Publishing
Advanced glycation end products (AGEs) play a major role in age-related diseases like Alzheimer''s disease. 1,2-dicarbonyl compounds, such as glyoxal (GO) and methylglyoxal (MGO), are involved in the formation of these AGEs. Thus, it was hypothesised that the progression of Alzheimer''s disease can be slowed down by lowering the concentration of 1,2-dicarbonyl compounds, which will consequently lead to a decrease in AGE formation. Therefore, the aim of this work was to establish an HPLC-method for the detection of glyoxal and methylglyoxal from cultured cells in order to determine the potential of different agents to lower the concentration of these 1,2-dicarbonyl compounds. Furthermore, it was assessed whether ALT-711 (Alagebrium), an AGE lowering agent, is an inhibitor of the enzyme thiamine diphosphokinase, due to its structural homology to the enzyme''s natural substrate thiamine. This enzyme is responsible for the formation of thiamine diphosphate, the co-factor of the enzyme...
 
- Генерация страницы: 0.05 секунд -